That's why some investors like Wood are interested in the stock. The company's upside potential is massive. And it got an even rosier outlook earlier this year when the U.S. Food and Drug Administration announced that it would be slowly phasing out animal testing in pre-clinical trials in favor of other methods, including AI-based models. It might look as though Recursion'a approach is the future. So why isn't the stock soaring, then? Recursion Pharmaceuticals (RXRX -4.84%) is not the most famous artificial ...